文献速递临床试验与 GCP真实世界研究与卫生经济

社区导航员计划减少难治性抑郁成人孤独感与抑郁的随机对照试验:试验方案

Randomised controlled trial of the Community Navigator programme to reduce loneliness and depression for adults with treatment-resistant depression in secondary community mental health services: trial protocol.
PubMed 文献 · Trials · 2023-10-06

本研究为研究者盲法、多中心、1:1随机对照试验,计划纳入306名在社区精神卫生团队接受治疗的难治性抑郁成人,检验在常规照护基础上增加社区导航员计划能否在8个月治疗结束时随访中减轻抑郁(PHQ-9自评)。对照组接受常规照护及本地社交团体活动信息手册,次要结局包括孤独感、焦虑、个人康复、自我效能、社交网络与社会身份等,并评估成本效果。

要点

  • 社区导航员计划由服务使用者与从业者共同设计,属新型社交干预,旨在减少孤独感并改善难治性抑郁患者的健康结局。
  • 参与者最多接受10次与社区导航员的个别会谈,可每2个月参加一次项目团体聚会,并可能获得适度经济支持以促进社交联结活动。
  • 主要假设为:在常规社区精神卫生团队照护基础上接受社区导航员计划者,8个月治疗结束时PHQ-9抑郁评分低于仅接受常规照护加信息手册的对照组。

核心结论

  • 本试验将提供社区导航员计划有效性与成本效果的确定性证据,并判断其能否被推荐用于实践。
  • 试验预计于2025年8月完成。

研究设计与样本

  • 研究者盲法、多中心、1:1随机对照试验,计划纳入N=306名在社区精神卫生团队(CMHTs)接受治疗的难治性抑郁(TRD)成人。
  • 干预组在常规CMHT照护基础上接受社区导航员计划,对照组接受常规CMHT照护及含本地社交团体与活动信息的册子。
  • 随访点为治疗结束时及14个月(即治疗结束随访后6个月)。
  • 试验于2022年7月8日在前瞻性注册(ISRCTN13205972)。

主要发现

  • 主要结局为8个月治疗结束时随访的PHQ-9自评抑郁评分。
  • 次要结局包括孤独感、焦虑、个人康复、自我效能、社交网络、社会身份。
  • 将收集健康相关生活质量与服务使用数据以分析成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New treatments are needed for people with treatment-resistant depression (TRD), who do not benefit from anti-depressants and many of whom do not recover fully with psychological treatments. The Community Navigator programme was co-produced with service users and practitioners. It is a novel social intervention which aims to reduce loneliness and thus improve health outcomes for people with TRD. Participants receive up to 10 individual meetings with a Community Navigator, who helps them to map their social world and set and enact goals to enhance their social connections and reduce loneliness. Participants may also access group meet-ups with others in the programme every 2 months, and may be offered modest financial support to enable activities to support social connections. METHODS: A researcher-blind, multi-site, 1:1 randomised controlled trial with N = 306 participants will test the effectiveness of the Community Navigator programme for people with TRD in secondary community mental health teams (CMHTs). Our primary hypothesis is that people who are offered the Community Navigator programme as an addition to usual CMHT care will be less depressed, assessed using the PHQ-9 self-report measure, at 8-month, end-of-treatment follow-up, compared to a control group receiving usual CMHT care and a booklet with information about local social groups and activities. We will follow participants up at end-of-treatment and at 14 months, 6 months after end-of-treatment follow-up. Secondary outcomes include the following: loneliness, anxiety, personal recovery, self-efficacy, social network, social identities. We will collect data about health-related quality of life and service use to investigate the cost-effectiveness of the Community Navigator programme. DISCUSSION: This trial will provide definitive evidence about the effectiveness and cost-effectiveness of the Community Navigator programme and whether it can be recommended for use in practice. The trial is due to finish in August 2025. TRIAL REGISTRATION: Prospectively registered on 8th July 2022 at: ISRCTN13205972.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Stefanidou T, Ambler G, Bartl G, et al. Randomised controlled trial of the Community Navigator programme to reduce loneliness and depression for adults with treatment-resistant depression in secondary community mental health services: trial protocol. Trials. 2023. PMID: 37803385. doi:10.1186/s13063-023-07684-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。